Company profile: Q BioMed
1.1 - Company Overview
Company description
- Provider of radiopharmaceutical and therapeutic candidates, including Strontium-89 Chloride Injection for relief of bone pain from skeletal metastases; Uttroside-B, a chemotherapeutic agent under development for liver cancer; QBM-001, a preclinical candidate targeting pediatric minimally verbal autism spectrum disorder; and MAN-01, a preclinical topical eyedrop for glaucoma.
Products and services
- MAN-01: A topical ophthalmic-grade eyedrop formulation in preclinical development for the treatment of glaucoma, engineered for ocular delivery with drop-based administration
- Strontium-89 Chloride Injection: A radiopharmaceutical-grade injectable used for relief of bone pain in patients with painful skeletal metastases, produced for clinical administration
- Uttroside-B: An investigational chemotherapeutic agent under development for the treatment of liver cancer, created for anticancer therapy in hepatic disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Q BioMed
GlycoEra
HQ: Switzerland
Website
- Description: Provider of extracellular protein degraders for autoimmune diseases, leveraging its CustomGlycan platform to design bi-functional biologics that selectively degrade circulating or membrane disease-causing proteins, such as autoantibodies, without broadly suppressing the immune system. Offerings include G-LyTACs, a custom glycan engineering platform, and protein degradation therapeutics with applications in oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GlycoEra company profile →
KAI Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel therapeutics through drug discovery and development, with multiple clinical-stage programs in cardiovascular disease, kidney disease, and pain; lead candidate KAI-9803 is in Phase 2b (PROTECTION AMI) evaluating reduction of myocardial injury in heart attack.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KAI Pharmaceuticals company profile →
Xenetic Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical drugs, cancer therapies and vaccines, centered on a DNase I oncology platform and NETs-targeting approaches for pancreatic and other solid tumors; collaborates with Volition on NETs-targeted adoptive cell therapies; holds sublicenses for PolyXen technology for blood/bleeding disorders and DNase enzyme-based cancer treatments; contracts cGMP manufacturing of recombinant Human DNase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xenetic Biosciences company profile →
Navamedic
HQ: Sweden
Website
- Description: Provider of pharmaceutical and medtech products, marketing to patients, hospitals and pharmacies. Offers prescription and OTC medicines and healthcare products; the Sippi next-generation digital urine meter; and a portfolio including Eroxon gel to help men achieve an erection, Flexilev for Parkinson’s, Absolut Torr antiperspirant, MedMade micronutrient supplements, and PKU and obesity education/support programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Navamedic company profile →
SynDevRx
HQ: United States
Website
- Description: Provider of polymer-based drug conjugates for oncology, including evexomostat (SDX-7320), a polymer-drug conjugate that releases a fumagillol derivative in vivo to target cancer and systemic metabolic hormone dysfunction. Sponsors clinical trials across various cancer types, provides an expanded access program, and advances a pipeline focused on cancers sensitive to metabolic hormones, leveraging metabo-oncology and polymer-drug conjugation to improve safety and activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SynDevRx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Q BioMed
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Q BioMed
2.2 - Growth funds investing in similar companies to Q BioMed
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Q BioMed
4.2 - Public trading comparable groups for Q BioMed
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →